Brought to you by 
University of Lyon, Pulsalys grant iDD biotech key patent and IP rights for mAb development
05 May 2017
Executive Summary
Pulsalys, the tech transfer office of the University of Lyon, granted iDD biotech SAS exclusive global rights to antibodies and patents targeting CK8 (cytokeratin 8), which iDD will use to scale up and enhance development of iDD005, its preclinical candidate against CK8.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
University of Lyon, Pulsalys grant iDD biotech key patent and IP rights for mAb development
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice